{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T22:57:24Z","timestamp":1775516244862,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study investigated treatment characteristics of Guillain-Barr\u00e9 syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale\u2009&gt;\u20092 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35\u201360]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36\u201313.10; <jats:italic>p<\/jats:italic>\u2009=\u20090.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31\u20135.40, <jats:italic>p<\/jats:italic>\u2009=\u20090.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20\u00a0years.<\/jats:p>","DOI":"10.1038\/s41598-021-98501-y","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T10:20:00Z","timestamp":1632738000000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-world treatment of adult patients with Guillain-Barr\u00e9 syndrome over the last two decades"],"prefix":"10.1038","volume":"11","author":[{"given":"Jakob","family":"Rath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gudrun","family":"Zulehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Schober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Grisold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Krenn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakan","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"Zimprich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"98501_CR1","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","volume":"15","author":"SE Leonhard","year":"2019","unstructured":"Leonhard, S. E. et al. Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps. Nat. Rev. Neurol. 15, 671\u2013683 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"98501_CR2","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","volume":"397","author":"N Shahrizaila","year":"2021","unstructured":"Shahrizaila, N., Lehmann, H. C. & Kuwabara, S. Guillain-Barr\u00e9 syndrome. Lancet 397, 1214\u20131228 (2021).","journal-title":"Lancet"},{"key":"98501_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002063.pub6","author":"RAC Hughes","year":"2014","unstructured":"Hughes, R. A. C., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6 (2014).","journal-title":"Cochrane Database Syst. Rev."},{"key":"98501_CR4","first-page":"CD001798","volume":"2","author":"S Chevret","year":"2017","unstructured":"Chevret, S., Hughes, R. A. & Annane, D. Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. 2, CD001798 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"98501_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CND.0000000000000119","volume":"18","author":"P Ortiz-Salas","year":"2016","unstructured":"Ortiz-Salas, P., Velez-Van-Meerbeke, A., Galvis-Gomez, C. A. & Rodriguez, Q. J. H. Human immunoglobulin versus plasmapheresis in Guillain-Barre syndrome and myasthenia gravis: A meta-analysis. J. Clin. Neuromuscul. Dis. 18, 1\u201311 (2016).","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"98501_CR6","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1093\/brain\/awm004","volume":"130","author":"RAC Hughes","year":"2007","unstructured":"Hughes, R. A. C. et al. Immunotherapy for Guillain-Barr\u00e9 syndrome: A systematic review. Brain 130, 2245\u20132257 (2007).","journal-title":"Brain"},{"key":"98501_CR7","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1136\/jnnp-2019-321496","volume":"91","author":"C Verboon","year":"2020","unstructured":"Verboon, C. et al. Original research: Second IVIg course in Guillain-Barr\u00e9 syndrome with poor prognosis: The non-randomised ISID study. J. Neurol. Neurosurg. Psychiatry 91, 113\u2013121 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"98501_CR8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","volume":"20","author":"C Walgaard","year":"2021","unstructured":"Walgaard, C. et al. Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): A double-blind, randomised, placebo-controlled trial. Lancet Neurol. 20, 275\u2013283 (2021).","journal-title":"Lancet Neurol."},{"key":"98501_CR9","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1212\/WNL.0000000000007719","volume":"93","author":"C Verboon","year":"2019","unstructured":"Verboon, C. et al. Current treatment practice of Guillain-Barr\u00e9 syndrome. Neurology 93, e59\u2013e76 (2019).","journal-title":"Neurology"},{"key":"98501_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/brain\/awt285","volume":"137","author":"C Fokke","year":"2014","unstructured":"Fokke, C. et al. Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria. Brain 137, 33\u201343 (2014).","journal-title":"Brain"},{"key":"98501_CR11","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","volume":"388","author":"HJ Willison","year":"2016","unstructured":"Willison, H. J., Jacobs, B. C. & van Doorn, P. A. Guillain-Barr\u00e9 syndrome. Lancet 388, 717\u2013727 (2016).","journal-title":"Lancet"},{"key":"98501_CR12","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/mus.880141111","volume":"14","author":"RP Kleyweg","year":"1991","unstructured":"Kleyweg, R. P., van der Mech\u00e9, F. G. & Schmitz, P. I. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome. Muscle Nerve 14, 1103\u20131109 (1991).","journal-title":"Muscle Nerve"},{"key":"98501_CR13","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial prednisolone in acute polyneuropathy. Lancet 2, 750\u2013753 (1978).","journal-title":"Lancet"},{"key":"98501_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","volume":"6","author":"R van Koningsveld","year":"2007","unstructured":"van Koningsveld, R. et al. A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome. Lancet Neurol. 6, 589\u2013594 (2007).","journal-title":"Lancet Neurol."},{"key":"98501_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1136\/jnnp-2014-307815","volume":"86","author":"YA Rajabally","year":"2015","unstructured":"Rajabally, Y. A., Durand, M.-C., Mitchell, J., Orlikowski, D. & Nicolas, G. Electrophysiological diagnosis of Guillain-Barr\u00e9 syndrome subtype: Could a single study suffice?. J. Neurol. Neurosurg. Psychiatry 86, 115\u2013119 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"98501_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1515\/cclm-2015-0253","volume":"54","author":"H Hegen","year":"2016","unstructured":"Hegen, H., Auer, M., Zeileis, A. & Deisenhammer, F. Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: Implications for increased clinical specificity. Clin. Chem. Lab. Med. 54, 285\u2013292 (2016).","journal-title":"Clin. Chem. Lab. Med."},{"key":"98501_CR17","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1373\/clinchem.2017.278267","volume":"63","author":"CR McCudden","year":"2017","unstructured":"McCudden, C. R., Brooks, J., Figurado, P. & Bourque, P. R. Cerebrospinal fluid total protein reference intervals derived from 20 years of patient data. Clin. Chem. 63, 1856\u20131865 (2017).","journal-title":"Clin. Chem."},{"key":"98501_CR18","doi-asserted-by":"crossref","unstructured":"The French Cooperative Group on Plasma Exchange in Guillain-Barr\u00e9 Syndrome. Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann. Neurol. 41, 298\u2013306 (1997).","DOI":"10.1002\/ana.410410304"},{"key":"98501_CR19","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1212\/WNL.56.8.1104","volume":"56","author":"M Mori","year":"2001","unstructured":"Mori, M., Kuwabara, S., Fukutake, T., Yuki, N. & Hattori, T. Clinical features and prognosis of Miller Fisher syndrome. Neurology 56, 1104\u20131106 (2001).","journal-title":"Neurology"},{"key":"98501_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004761.pub2","author":"JR Overell","year":"2007","unstructured":"Overell, J. R., Hsieh, S. T., Odaka, M., Yuki, N. & Willison, H. J. Treatment for Fisher syndrome, Bickerstaff\u2019s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD004761.pub2 (2007).","journal-title":"Cochrane Database Syst. Rev."},{"key":"98501_CR21","first-page":"CD001446","volume":"10","author":"RA Hughes","year":"2016","unstructured":"Hughes, R. A., Brassington, R., Gunn, A. A. & van Doorn, P. A. Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst. Rev. 10, CD001446 (2016).","journal-title":"Cochrane Database Syst. Rev."},{"key":"98501_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","volume":"363","author":"R van Koningsveld","year":"2004","unstructured":"van Koningsveld, R. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome: Randomised trial. Lancet 363, 192\u2013196 (2004).","journal-title":"Lancet"},{"key":"98501_CR23","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","volume":"74","author":"L Ruts","year":"2010","unstructured":"Ruts, L., Drenthen, J., Jacobs, B. C., van Doorn, P. A. & Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: A prospective study. Neurology 74, 1680\u20131686 (2010).","journal-title":"Neurology"},{"key":"98501_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/jnnp-2016-314862","volume":"88","author":"C Verboon","year":"2017","unstructured":"Verboon, C., van Doorn, P. A. & Jacobs, B. C. Treatment dilemmas in Guillain-Barr\u00e9 syndrome. J. Neurol. Neurosurg. Psychiatry 88, 346\u2013352 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98501-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98501-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98501-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T16:17:14Z","timestamp":1670084234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-98501-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["98501"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-98501-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"assertion":[{"value":"10 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19170"}}